All In Biotech

Drug Trial Radar · NCT04002297

A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 510 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

510

Actual

Start

Aug 20, 2019

Primary completion

Apr 27, 2026

Study completion Sep 30, 2031

Sponsor

Lead sponsor
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Jun 28, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma (MCL) who are not eligible for stem cell transplantation.

Conditions

  • Mantle Cell Lymphoma; Non-Hodgkin Lymphoma

Interventions

  • zanubrutinibDrug

    Administered as two 80 mg capsules by mouth twice a day

  • bendamustineDrug

    Administered intravenously at a dose of 90 mg/m2/day on Days 1 and 2 of Cycles 1 to 6

  • rituximabDrug

    Administered intravenously at a dose of 375 mg/m2 on Day 1 of Cycles 1 to 6

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) determined by independent central reviewTime frame: Up to approximately 7 years

Locations

176 sites in 22 countries. Site status is shown where the registry gives one.

  • Chao Family Comprehensive Cancer Center

    Orange, California

  • Rush University Medical Center

    Chicago, Illinois

  • Beth Israel Deaconess Medical Center (Bidmc)

    Boston, Massachusetts

  • University of Michigan Health System

    Ann Arbor, Michigan

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • Icahn School of Medicine At Mount Sinai

    New York, New York

  • Clinical Research Alliance, Inc

    Westbury, New York

  • Providence Portland Medical Center

    Portland, Oregon

  • West Penn Hospital

    Pittsburgh, Pennsylvania

  • The University of Texas Md Anderson Cancer Center

    Houston, Texas

  • Joe Arrington Cancer Research and Treatment Center

    Lubbock, Texas

  • Seattle Cancer Care Alliance

    Seattle, Washington

  • Canberra Hospital

    Garran, Australian Capital Territory, Australia

  • Concord Repatriation General Hospital

    Concord, New South Wales, Australia

  • The Tweed Valley Hospital

    Cudgen, New South Wales, Australia

  • Saint Vincents Hospital Sydney

    Darlinghurst, New South Wales, Australia

  • Gosford Hospital

    Gosford, New South Wales, Australia

  • Calvary Mater Newcastle

    Waratah, New South Wales, Australia

  • Sunshine Coast Hospital and Health Service

    Birtinya, Queensland, Australia

  • Icon Cancer Foundation

    South Brisbane, Queensland, Australia

  • Flinders Medical Centre

    Bedford PK, South Australia, Australia

  • Royal Hobart Hospital

    Hobart, Tasmania, Australia

  • Monash Health

    Clayton, Victoria, Australia

  • St Vincents Hospital Melbourne

    Fitzroy, Victoria, Australia

  • Peninsula Private Hospital

    Frankston, Victoria, Australia

  • Barwon Health the Geelong Hospital

    Geelong, Victoria, Australia

  • Royal Perth Hospital

    Perth, Western Australia, Australia

  • Ordensklinikum Linz Gmbh Elisabethinen

    Linz, Austria

  • Universitatsklinik Fur Innere Medizin Iii Universitatsklinikum Der Pmu Landeskrankenhaus Salzburg

    Salzburg, Austria

  • Medical University Vienna Oncology

    Vienna, Austria

  • Az Sint Jan Brugge

    Bruges, Belgium

  • Universitair Ziekenhuis Brussel

    Brussels, Belgium

  • Uz Antwerpen

    Edegem, Belgium

  • Az Groeninge Campus Loofstraat

    Kortrijk, Belgium

  • Centre Hospitalier Universitaire (Chu) de Liege Site Du Sart Tilman

    Liège, Belgium

  • Centre Hospitalier Universitaire Universite Catholique de Louvain Site Godinne

    Yvoir, Belgium

  • The Ottawa Hospital

    Ottawa, Ontario, Canada

  • Ciusss de Lestrie Chus

    Sherbrooke, Quebec, Canada

  • Peking University Peoples Hospital

    Beijing, Beijing Municipality, China

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

Showing 40 of 176 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.